KRAS mutations cause constitutive activation of the MAP kinase pathway, making colorectal cancers resistant to anti‑EGFR monoclonal antibodies. Testing for KRAS/NRAS status guides use of cetuximab or panitumumab in me...
Open this topic in Core Concepts